CMG-901 is a monoclonal antibody conjugated commercialized by KeyMed Biosciences, with a leading Phase III program in Adenocarcinoma Of The Gastroesophageal Junction. According to Globaldata, it is involved in 5 clinical trials, of which 4 are ongoing, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of CMG-901’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Smarter leaders trust GlobalData
The revenue for CMG-901 is expected to reach an annual total of $16 mn by 2039 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
CMG-901 Overview
AZD-0901 is under development for the treatment of advanced solid tumors including pancreatic cancer, pancreatic ductal adenocarcinoma, gastric cancer, adenocarcinoma of the gastroesophageal junction and Gastroesophageal (GE) Junction Carcinomas. It is administered through intravenous route. It is an monomethyl auristatin E (MMAE) antibody drug conjugate acts by targeting cells expressing claudin 18.2.
KeyMed Biosciences Overview
KeyMed Biosciences engages in the research and development of biological therapies for the treatment of autoimmunity and oncology diseases. The company is headquartered in Chengdu, Sichuan, China.
The company reported revenues of (Renminbi) CNY100.1 million for the fiscal year ended December 2022 (FY2022), a decrease of 9.3% over FY2021. The operating loss of the company was CNY285.5 million in FY2022, compared to an operating loss of CNY3,880.8 million in FY2021. The net loss of the company was CNY308.1 million in FY2022, compared to a net loss of CNY3,887.3 million in FY2021.
For a complete picture of CMG-901’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
